Detalles de la búsqueda
1.
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer.
Proc Natl Acad Sci U S A
; 117(22): 12288-12294, 2020 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32430334
2.
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res
; 18(1): 34, 2016 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26979312
3.
Trastuzumab emtansine for HER2-positive advanced breast cancer.
N Engl J Med
; 367(19): 1783-91, 2012 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-23020162
4.
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
Breast Cancer Res
; 16(3): R50, 2014 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24887458
5.
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Cancer
; 120(5): 642-51, 2014 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24222194
6.
Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Oncologist
; 19(9): 901-8, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25085897
7.
Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach.
Genome Med
; 11(1): 39, 2019 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31221204
8.
Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer.
Adv Ther
; 36(8): 2122-2136, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31140124
9.
Phase I Trial of Everolimus and Capecitabine in Metastatic HER2- Breast Cancer.
Clin Breast Cancer
; 17(6): 418-426, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28385537
10.
Author's Response to "A Letter in Support of Real-World RECIST".
Adv Ther
; 37(4): 1691-1693, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32056085
11.
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Cancer Chemother Pharmacol
; 74(2): 399-410, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24939213
12.
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Clin Cancer Res
; 20(2): 456-68, 2014 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24097864
13.
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
J Clin Oncol
; 31(9): 1157-63, 2013 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23382472
14.
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
J Clin Oncol
; 30(26): 3234-41, 2012 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22649126
15.
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
Clin Cancer Res
; 17(20): 6437-47, 2011 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22003071
Resultados
1 -
15
de 15
1
Próxima >
>>